BiVictriX Therapeutics plc (BVX.L)
BiVictriX Therapeutics plc, a biotechnology company, engages in the development of cancer therapies in the United Kingdom. The company develops Bi-Cygni therapeutics, which are selective for cancer types. Its lead program is BVX001, focuses on acute myeloid leukaemia, as well as develops BVX002 and BVX003 for various blood cancers and solid tumours. BiVictriX Therapeutics plc was founded in 2016 and is headquartered in Macclesfield, the United Kingdom.
Company Info
Highlights
£8.25M
-£0.04
-£90.00K
-£1.59M
£7.00 - £14.00
£66.00
Share Price Chart
Loading data...
Compare to other instruments
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
Performance Chart
The chart shows the growth of an initial investment of £10,000 in BiVictriX Therapeutics plc, comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.
Returns By Period
BVX.L
N/A
N/A
N/A
N/A
N/A
N/A
^GSPC (Benchmark)
2.90%
3.70%
10.94%
22.18%
12.41%
11.21%
Monthly Returns
The table below presents the monthly returns of BVX.L, with color gradation from worst to best to easily spot seasonal factors. Returns are adjusted for dividends.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024 | 9.52% | 0.00% | -2.17% | 2.22% | -0.00% | 8.70% | 4.00% | -42.31% | -4.76% | ||||
| 2023 | 2.94% | 0.00% | -20.00% | 7.14% | -13.33% | 15.38% | -6.67% | 3.57% | -3.45% | -7.14% | -15.38% | -4.55% | -38.24% |
| 2022 | -5.08% | -21.43% | 6.82% | 6.38% | -8.00% | -13.04% | 2.50% | -29.27% | 48.28% | -2.33% | -28.57% | 13.33% | -42.37% |
| 2021 | -19.61% | -4.88% | 0.00% | 23.08% | 22.92% | 15.69% |
Risk-Adjusted Performance
Risk-Adjusted Performance Rank
The current rank of BVX.L is 13, meaning it’s performing worse than 87% of other stocks on our website when it comes to balancing risk and reward. Below is a breakdown of how it compares using common performance measures.
Risk-Adjusted Performance Indicators
The charts below present risk-adjusted performance metrics for BiVictriX Therapeutics plc (BVX.L) and compare them to a chosen benchmark (^GSPC). These indicators evaluate an investment's returns against its associated risks.
Dividends
Dividend History
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Worst Drawdowns
The table below displays the maximum drawdowns of the BiVictriX Therapeutics plc. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the BiVictriX Therapeutics plc was 77.61%, occurring on Aug 29, 2024. The portfolio has not yet recovered.
Depth | Start | To Bottom | Bottom | To Recover | End | Total |
|---|---|---|---|---|---|---|
| -77.61% | Jan 14, 2022 | 661 | Aug 29, 2024 | — | — | — |
| -29.41% | Aug 12, 2021 | 27 | Sep 20, 2021 | 40 | Nov 15, 2021 | 67 |
| -9.43% | Nov 19, 2021 | 5 | Nov 25, 2021 | 18 | Dec 21, 2021 | 23 |
| -5.66% | Nov 16, 2021 | 1 | Nov 16, 2021 | 2 | Nov 18, 2021 | 3 |
Volatility
Volatility Chart
The current BiVictriX Therapeutics plc volatility is 54.07%, representing the average percentage change in the investments's value, either up or down over the past month. The chart below shows the rolling one-month volatility.
Financials
Financial Performance
Historical P/E Ratio Chart
The chart below displays the historical trend of the price-to-earnings (P/E) ratio for BiVictriX Therapeutics plc.
Loading data...
Income Statement
| TTM | |
|---|---|
Revenue | |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
Operating Expenses | |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
Income | |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |